Browsing by Subject "Erlotinib"
Now showing items 1-13 of 13
-
Article
Cancer and pregnancy: What should we know about the management with systemic treatment of pregnant women with cancer?
(2011)The incidence of cancer during pregnancy is a rare phenomenon and is estimated to occur in 1:1000 pregnancies. This co-existence is likely to rise since the delay of childbearing to the later reproductive age is nowadays ...
-
Article
Cancer of unknown primary site: 20 questions to be answered
(2010)Cancer of unknown primary (CUP) is a common, well-recognized and heterogeneous clinical syndrome. Patients with CUP present with metastatic disease in the absence of an identifiable primary tumour despite a diagnostic ...
-
Article
Carcinoma of unknown primary (CUP)
(2009)Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests ...
-
Article
Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): Report of a case and review of the literature
(2009)The clinical manifestation of disseminated intravascular coagulation (DIC) as paraneoplastic phenomenon is common in patients with lung cancer (especially in those with non small cell lung cancer).Surprisingly, only few ...
-
Article
Forty years experience of treating cancer of unknown primary
(2007)Cancer of unknown primary site (CUP) is not a rare tumour. It accounts as the seventh to eighth most frequently diagnosed cancer in a general medical oncology service. Since CUP is not a homogeneous disease and it consists ...
-
Article
Lung cancer in the pregnant woman: To treat or not to treat, that is the question
(2010)Lung cancer in pregnancy is a rare situation; however, it is increasingly reported in the past two decades. The association might be more encountered in the coming years due to the rising trends of cigarette smoking among ...
-
Article
Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review
(2009)Background: Gene expression profiling platforms were recently shown to accurately assign cancer of unknown primary (CUP) to a primary tissue of origin, with unknown impact on patient outcome. We examined chemotherapy ...
-
Article
Neuroendocrine carcinoma of unknown primary: A systematic review of the literature and a comparative study with other neuroendocrine tumors
(2011)Introduction: Neuroendocrine carcinomas of unknown primary (NCUP) represent a specific subset with relatively favorable prognosis. Data on biology, management and outcome of NCUP patients have not been systematically ...
-
Article
Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets
(2012)Cancer of unknown primary sites (CUP) is a compilation of various malignant entities-the majority of which behave aggressively and carry poor prognosis. CUP is classified into two different clinicopathological groups: the ...
-
Article
Perspectives for targeted therapies in cancer of unknown primary site
(2006)Cancer of unknown primary site (CUP) ranks as the fourth most common cause of cancer deaths. Regression of the primary, early development of systemic metastases and resistance to therapy are hallmarks of this heterogeneous ...
-
Article
Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management
(2012)The toxicity of cancer chemotherapy is among the most important factors limiting its use. Clear delineation and communication of benefits and risks is an essential component of treatment decisions. Gastrointestinal toxicity ...
-
Article
Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors
(2009)The treatment for patients with unknown primary carcinoma, particularly those with unfavorable prognosis factors, has changed in the last decade, and continues to evolve. Empiric chemotherapy trials reported since 2000 ...
-
Article
Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors
(2010)The association of cancer and pregnancy is increasingly encountered nowadays in clinical practice. Due to the relative rarity of the situation, it lacks a systematized approach. Different systemic therapies are used in ...